AB Science SA AB

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS DEVELOPMENT PLAN AND FINANCIAL CALENDAR FOLLOWING A SPONSOR GOOD CLINICAL PRACTICE INSPECTION Confirmation of the relevance of having, among the first decisions of the new management, given priority to the development of a new quality management system Expected resumption of the AB8939 phase 1 (acute myeloid leukemia) in the first quarter of 2027, followed by the masitinib phase 3 (amyotrophic lateral sclerosis) in the last quarter of 2027, subj

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL SETTLEMENT AND DELIVERY OF SECURITIES ISSUED AS PART OF ITS €14.2 MILLION PRIVATE PLACEMENT ANNOUNCED ON AUGUST 10, 2026 Paris, August 17, 2026, 7.30am CET AB Science S.A. (the “Company” or “AB Science,” Euronext – FR0010557264 – AB) today announces the successful settlement and delivery of the securities issued as part of its capital increases subscribed to by a limited number of investors and announced on August 10, 2026 (the “Private Placement

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 14.2 MILLION PRIVATE PLACEMENT, PRIMARILY SUSBCRIBED BY LONG TERM INVESTOR AB SCIENCE CASH POSITION IS AROUND EUR 23 MILLION AFTER THIS PRIVATE PLACEMENT, THEREBY ALLOWING THE COMPANY TO CARRY-OUT WITHOUT ANY ADDITIONAL NEAR-TERM FINANCING THE FIRST STEPS OF ITS STRATEGIC PLAN TO BE FINALIZED AND ANNOUNCED IN SEPTEMBER Paris, August 10, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) ann

The Alzheimer's disease treatment landscape is experiencing a major transformation with the introduction of disease-modifying therapies that target fundamental disease mechanisms, particularly amyloid-β pathology. Among these, LEQEMBI (lecanemab) has become a leading biologic for patients with early-stage Alzheimer's disease, demonstrating its ability to slow cognitive and functional deterioration in biomarker-confirmed individuals. Regulatory approvals across key global markets have strengthene

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS Paris, July 10, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral s

PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.3 MILLION PRIVATE PLACEMENT Paris, July 1st, 2026, 8am AB Science S.A. (the “Company” or “AB Science”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.3 million subscribed by a limited number of investors (the “Private Placement”). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority

PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2042 THIS POSITIVE DECISION FROM THE USA PATENT OFFICE ADDS TO THE COVERAGE ALREADY GRANTED IN EUROPE Paris, June 17, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has formally granted a patent for methods of treating metastatic castrate resistant prostate can

Masitinib's market opportunities lie in its broad application across ALS, MS, and prostate cancer with regulatory backing from FDA and EMA. Robust IP and biomarker strategies enhance its appeal, while strong clinical data supports growth in various neurodegenerative and cancer indications.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Masitinib Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report outlines its potential application across

PRESS RELEASE AB SCIENCE PRESENTS ITS ANNUAL FINANCIAL RESULTS AS OF 31 DECEMBER 2025 AND KEY EVENTS FOR THE PERIOD Financial and corporate position Operating loss of €3.8 million as of 31 December 2025, down 38% compared with the 2025 financial year (excluding non-recurring items)Cash position of €10.2 million as of 31 December 2025, plus €3.2 million from the private placement carried out in April 2026Final agreement on the renegotiation of the repayment terms of its loans with all financial c

PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditorsThis agreement provides for a two-year deferral of repayment of the State-Guaranteed Loans and a 12-month deferral of the repayment date of the EIB Covid creditThe savings over the period will be invested in R&D Paris, April 27, 2026, 6pm CET AB Science SA (Euronext - FR0010557264 - A

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III TRIAL IN AMYOTROPHIC LATERAL SCLEROSIS THE POLICY COVERS UP TO EUR 25 MILLION OF TRIAL COSTS IN THE EVENT OF CLINICAL FAILURE, WITH ZERO DEDUCTIBLE THIS RISK-TRANSFER STRUCTURE PROTECTS SHAREHOLDER CAPITAL AND SIGNALS INSTITUTIONAL CONFIDENCE IN THE MASITINIB PROGRAMME AB SCIENCE IMPLEMENTS A VOLUNTARY TEMPORARY HALT IN EUROPE OF ITS CLINICAL TRIALS, BE